The Manufacturers Life Insurance Company Sells 22,079 Shares of Vaxcyte, Inc. $PCVX

The Manufacturers Life Insurance Company lowered its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 20.4% during the 1st quarter, HoldingsChannel reports. The firm owned 86,366 shares of the company’s stock after selling 22,079 shares during the period. The Manufacturers Life Insurance Company’s holdings in Vaxcyte were worth $5,019,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Maverick Capital Ltd. raised its stake in Vaxcyte by 1.7% during the 1st quarter. Maverick Capital Ltd. now owns 1,377,738 shares of the company’s stock valued at $80,060,000 after buying an additional 23,501 shares during the last quarter. Quantinno Capital Management LP boosted its stake in shares of Vaxcyte by 48.7% in the 1st quarter. Quantinno Capital Management LP now owns 21,563 shares of the company’s stock worth $1,253,000 after buying an additional 7,062 shares during the last quarter. First Light Asset Management LLC bought a new stake in shares of Vaxcyte in the first quarter worth $8,239,000. SummitTX Capital L.P. grew its holdings in shares of Vaxcyte by 403.3% in the first quarter. SummitTX Capital L.P. now owns 74,842 shares of the company’s stock worth $4,349,000 after acquiring an additional 59,973 shares during the period. Finally, Inceptionr LLC purchased a new stake in Vaxcyte during the first quarter valued at $334,000. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Performance

PCVX opened at $58.89 on Friday. The stock has a market cap of $8.50 billion, a price-to-earnings ratio of -7.72 and a beta of 1.23. The firm’s fifty day moving average is $53.72 and its 200 day moving average is $55.19. Vaxcyte, Inc. has a fifty-two week low of $29.08 and a fifty-two week high of $65.00.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.09. During the same period in the previous year, the business posted ($1.22) earnings per share. On average, equities research analysts predict that Vaxcyte, Inc. will post -7.91 earnings per share for the current year.

More Vaxcyte News

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Quarterly loss beat expectations: Vaxcyte reported second-quarter 2026 EPS of negative $1.97, better than analysts’ consensus estimate of negative $2.06. However, the loss was wider than the negative $1.22 reported in the year-earlier quarter. Vaxcyte quarterly earnings release
• Positive Sentiment: Multiple clinical catalysts are ahead: Topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial are expected in the fourth quarter of 2026. Results from OPUS-2 and OPUS-3 are expected in the first half of 2027, while infant VAX-31 data are expected by the end of the first half of 2027. Vaxcyte second-quarter business update
• Positive Sentiment: Strong liquidity supports development: Vaxcyte held approximately $2.5 billion in cash, cash equivalents and investments at June 30, 2026. The balance sheet reduces near-term financing concerns as the company advances its late-stage vaccine programs and VAX-A1.
• Neutral Sentiment: Institutional ownership remains high: Several funds, including Royal Bank of Canada, UBS Asset Management and Cetera Investment Advisers, increased their positions recently. Institutional investors and hedge funds collectively own approximately 96.8% of outstanding shares.
• Negative Sentiment: Executives reported stock sales: The CFO, COO and another insider sold a combined 29,250 shares worth roughly $1.6 million. The transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may still weigh modestly on sentiment. Vaxcyte insider selling report
• Negative Sentiment: Losses are expected to continue: Analysts forecast a full-year 2026 loss of approximately $7.91 per share, underscoring Vaxcyte’s dependence on successful clinical execution and future commercialization.

Insiders Place Their Bets

In related news, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $49.52, for a total value of $111,420.00. Following the transaction, the chief operating officer directly owned 158,494 shares of the company’s stock, valued at approximately $7,848,622.88. The trade was a 1.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harpreet S. Dhaliwal sold 17,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $55.00, for a total value of $935,000.00. Following the completion of the transaction, the insider owned 76,756 shares of the company’s stock, valued at $4,221,580. The trade was a 18.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 120,646 shares of company stock worth $6,570,810. 3.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on PCVX. Zacks Research cut Vaxcyte from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Wall Street Zen lowered shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $86.00.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.